Julie C Lauffenburger1, Joan E Landon2, Michael A Fischer2. 1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA. jlauffenburger@bwh.harvard.edu. 2. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.
Abstract
BACKGROUND: New trial evidence suggests that many patients may require more aggressive pharmacologic management to achieve lower blood pressure goals. Especially when first initiating anti-hypertensive treatment, it is unknown whether starting patients on multiple medications may be better for long-term adherence and persistence compared with starting one medication. OBJECTIVE: To examine contemporary patterns of anti-hypertensive therapy initiation and compare long-term adherence and persistence among patients initiating fixed-dose combinations and single anti-hypertensive therapies. DESIGN: Retrospective cohort study. PATIENTS: Using claims from a large nationwide insurer, we identified all patients initiating oral hypertension treatment from 2009 to 2013. We categorized patients into three categories based on the number and type of anti-hypertensive medications they initiated: a fixed-dose combination, a multi-pill combination or a single therapy. MAIN MEASURES: The primary outcome was persistence to any anti-hypertensive medication, either the initiated medication or other anti-hypertensive, 12 months after initiation in administrative claims. We also measured adherence to at least one anti-hypertensive in the 12 months after initiation and refilling at least one anti-hypertensive medication as outcomes. Full adherence was defined as having ≥80% of potential days covered with medication. Multivariable modified Poisson regression models were used to examine the association between initiating a fixed-dose combination anti-hypertensive and medication outcomes. KEY RESULTS: Of the 484,493 patients who initiated oral anti-hypertensives, 78,958 patients initiated fixed-dose combinations, 383,269 initiated a single therapy, and 22,266 initiated multi-pill combinations. Patients initiating fixed-dose combinations were 9% more likely to be persistent (relative risk [RR]: 1.09, 95% CI: 1.08-1.10) and 13% more likely to be adherent (RR: 1.13 95% CI: 1.11-1.14) than those who started on a single anti-hypertensive therapy. Refill rates were also slightly higher among fixed-dose combination initiators. CONCLUSIONS: Fixed-dose combination pills appear to enhance adherence and persistence to anti-hypertensive medications among commercially insured patients starting treatment compared with single therapy.
BACKGROUND: New trial evidence suggests that many patients may require more aggressive pharmacologic management to achieve lower blood pressure goals. Especially when first initiating anti-hypertensive treatment, it is unknown whether starting patients on multiple medications may be better for long-term adherence and persistence compared with starting one medication. OBJECTIVE: To examine contemporary patterns of anti-hypertensive therapy initiation and compare long-term adherence and persistence among patients initiating fixed-dose combinations and single anti-hypertensive therapies. DESIGN: Retrospective cohort study. PATIENTS: Using claims from a large nationwide insurer, we identified all patients initiating oral hypertension treatment from 2009 to 2013. We categorized patients into three categories based on the number and type of anti-hypertensive medications they initiated: a fixed-dose combination, a multi-pill combination or a single therapy. MAIN MEASURES: The primary outcome was persistence to any anti-hypertensive medication, either the initiated medication or other anti-hypertensive, 12 months after initiation in administrative claims. We also measured adherence to at least one anti-hypertensive in the 12 months after initiation and refilling at least one anti-hypertensive medication as outcomes. Full adherence was defined as having ≥80% of potential days covered with medication. Multivariable modified Poisson regression models were used to examine the association between initiating a fixed-dose combination anti-hypertensive and medication outcomes. KEY RESULTS: Of the 484,493 patients who initiated oral anti-hypertensives, 78,958 patients initiated fixed-dose combinations, 383,269 initiated a single therapy, and 22,266 initiated multi-pill combinations. Patients initiating fixed-dose combinations were 9% more likely to be persistent (relative risk [RR]: 1.09, 95% CI: 1.08-1.10) and 13% more likely to be adherent (RR: 1.13 95% CI: 1.11-1.14) than those who started on a single anti-hypertensive therapy. Refill rates were also slightly higher among fixed-dose combination initiators. CONCLUSIONS: Fixed-dose combination pills appear to enhance adherence and persistence to anti-hypertensive medications among commercially insured patients starting treatment compared with single therapy.
Authors: Niteesh K Choudhry; Robert J Glynn; Jerry Avorn; Joy L Lee; Troyen A Brennan; Lonny Reisman; Michele Toscano; Raisa Levin; Olga S Matlin; Elliott M Antman; William H Shrank Journal: Am Heart J Date: 2013-10-17 Impact factor: 4.749
Authors: Richard A Hansen; Mimi M Kim; Liping Song; Wanzhu Tu; Jingwei Wu; Michael D Murray Journal: Ann Pharmacother Date: 2009-03-03 Impact factor: 3.154
Authors: Julie A Schmittdiel; Gregory A Nichols; Wendy Dyer; John F Steiner; Andrew J Karter; Marsha A Raebel Journal: Med Care Date: 2015-04 Impact factor: 2.983
Authors: Robert B Hanlin; Irfan M Asif; Gregory Wozniak; Susan E Sutherland; Bijal Shah; Jianing Yang; Robert A Davis; Sean T Bryan; Michael Rakotz; Brent M Egan Journal: J Clin Hypertens (Greenwich) Date: 2018-01-05 Impact factor: 3.738
Authors: Brent M Egan; Susan E Sutherland; Michael Rakotz; Jianing Yang; R Bruce Hanlin; Robert A Davis; Gregory Wozniak Journal: Hypertension Date: 2018-12 Impact factor: 10.190
Authors: Jaram Park; Jeong-Whun Kim; Borim Ryu; Eunyoung Heo; Se Young Jung; Sooyoung Yoo Journal: J Med Internet Res Date: 2019-02-15 Impact factor: 5.428
Authors: Jingjing Pan; Lian Wu; Huichuan Wang; Tao Lei; Bin Hu; Xiaorong Xue; Qiongge Li Journal: Medicine (Baltimore) Date: 2019-07 Impact factor: 1.817
Authors: Claudio Borghi; Jiguang Wang; Anton V Rodionov; Martin Rosas; Il Suk Sohn; Luis Alcocer; William J Valentine; Daniela Deroche-Chibedi; Denis Granados; Davide Croce Journal: Int J Cardiol Cardiovasc Risk Prev Date: 2021-08-08